Dose Extrapolation

Overview

Dose extrapolation is the process of estimating a comparable dose of a substance across different species, body sizes, or populations. In peptide research, it most commonly refers to the translation of doses used in animal studies (typically rodent models) into human-equivalent doses (HED) — an essential but inherently uncertain step in interpreting preclinical data.

Because metabolic rate, organ function, and drug clearance do not scale linearly with body weight, simple weight-based conversion (mg/kg) often overestimates or underestimates the equivalent human dose. Instead, dose extrapolation typically relies on body surface area (BSA) normalization or allometric scaling, which account for the relationship between body size and metabolic rate across species.

Detailed Explanation

Body Surface Area Method

The most widely referenced approach uses species-specific conversion factors based on body surface area. The general formula is:

HED (mg/kg) = Animal Dose (mg/kg) x (Animal Km / Human Km)

Where Km is the ratio of body weight (kg) to body surface area (m2) for each species:

For a mouse-to-human conversion, this yields a factor of approximately 12.3 (3/37 x 60/0.02, simplified), meaning the mg/kg dose in mice is divided by approximately 12.3 to obtain the HED in mg/kg.

Allometric Scaling

Allometric scaling uses power-law relationships between body weight and physiological parameters (clearance, half-life, volume of distribution) to predict pharmacokinetic behavior across species. The general form is:

Y = a x W^b

Where Y is the parameter of interest, W is body weight, a is a coefficient, and b is the allometric exponent (typically 0.67–0.75 for clearance-related parameters).

Limitations

Dose extrapolation carries significant uncertainty:

• Species differences in metabolism — Enzyme expression, receptor density, and protein binding can differ substantially between species, and BSA scaling does not account for these factors.
• Route-dependent absorption — A peptide's bioavailability may differ between species due to differences in subcutaneous tissue composition, enzymatic activity, and blood flow.
• Pharmacodynamic differences — Even if equivalent plasma concentrations are achieved, the biological response may differ due to species-specific receptor affinities or signaling pathway differences.
• Peptide-specific challenges — Peptides are particularly difficult to extrapolate because their pharmacokinetics (short half-lives, rapid enzymatic degradation) can vary greatly between species.

Relevance to Peptide Research

Dose extrapolation is one of the most frequently cited — and most frequently misapplied — concepts in the peptide research community:

• Interpreting animal data — Most peptide research originates from animal studies. Understanding the limitations of dose extrapolation is critical for interpreting what these studies may or may not suggest about human-relevant doses.
• Common errors — Direct mg/kg conversion from rodent to human without BSA correction typically overestimates the projected HED by a factor of 6–12x. Conversely, some online calculators apply corrections incorrectly.
• Multiple endpoints — The extrapolated dose depends on which endpoint is being targeted. An effective dose for one outcome in an animal model may not translate to the same outcome in humans.
• Safety margins — Regulatory science typically applies additional safety factors (often 10x or more) to extrapolated doses to account for interspecies uncertainty.

Examples

• A study reports that BPC-157 at 10 mcg/kg in rats produces measurable effects. Using BSA conversion (Km ratio 6/37), the projected HED is approximately 1.6 mcg/kg, substantially lower than the rodent dose on a mg/kg basis.
• A researcher reviewing a mouse study notes the effective dose was 1 mg/kg. Applying the mouse-to-human BSA factor (3/37), the estimated HED is approximately 0.08 mg/kg — about 5.6 mg for a 70 kg individual.
• A peptide shows efficacy at 100 mcg/kg in rats, but its half-life in humans is known to be three times longer than in rats, suggesting that the BSA-extrapolated HED may itself be an overestimate.

Related Terms

• Dose-Response Curve — The relationship between dose and effect that extrapolation attempts to translate
• Pharmacokinetics — Species-specific PK parameters that influence dose extrapolation
• Bioavailability — Route-dependent absorption that may differ between species
• Volume of Distribution — A PK parameter used in allometric scaling
• AUC — Area under the curve, often the target parameter for dose equivalence